Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 389

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 389
---
 |        |
| Name                                                                               |     | Registered Office                                          |     | Nature of Business |     | Notes  |
| Biodexa Limited (formerly Midatech Limited)                                        |     | 1 Caspian Point, Caspian Way, Cardiff,                     
 CF10 4DQ                                                   |     | Trading company    |     |        |
| Biodexa Pharmaceuticals (Wales) Limited (formerly Midatech Pharma (Wales) Limited) |     | 1 Caspian Point, Caspian Way, Cardiff,                     
 CF10 4DQ                                                   |     | Trading company    |     |        |
| Haaland UK Limited                                                                 |     | 1 Caspian Point, Caspian Way, Cardiff,                     
 CF10 4DQ                                                   |     | Dormant            |     |        |
| PharMida AG                                                                        |     | c/o Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland |     | Dormant            |     | -a) (b |

Notes:

| (a) | Wholly owned subsidiary of Biodexa Limited. |

| (b) | PharMida AG became dormant in January 2016. |

| F-52 |

| 13 | Trade and other receivables |

| Schedule of trade and other receivables |     |            |     |            |     |            |
|                                         |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Trade receivables                       |     |          – |     |        329 |     |         33 |
| Prepayments                             |     |        355 |     |        376 |     |        607 |
| Other receivables                       |     |        282 |     |        301 |     |        394 |
| Total trade and other receivables       |     |        637 |     |      1,006 |     |      1,034 |
| Less: non-current portion               |     |          – |     |          – |     |          – |
| Current portion                         |     |        637 |     |      1,006 |     |      1,034 |

The Group has applied
the practical expedient permitted by IFRS 15 to not disclose the transaction price allocated to performance obligations unsatisfied (or
partially